Which Liver Enzymes Does Lipitor Increase?
Lipitor (atorvastatin), a statin used to lower cholesterol, can elevate liver enzymes as a side effect, primarily indicating potential liver stress or injury. It specifically increases alanine aminotransferase (ALT) and aspartate aminotransferase (AST), with ALT elevations being more common and sensitive.[1][2]
How Common Are These Elevations?
In clinical trials, persistent ALT or AST elevations above three times the upper limit of normal occurred in about 0.6-3% of patients on Lipitor doses of 10-80 mg, usually resolving after dose reduction or discontinuation. Higher doses (like 80 mg) show slightly higher rates, around 2-3%.[1][3]
Why Do ALT and AST Rise with Lipitor?
Statins like Lipitor inhibit HMG-CoA reductase in the liver, which may disrupt hepatocyte function and cause mild, reversible transaminitis (elevated transaminases). ALT is liver-specific, while AST is found in liver, heart, and muscle, so rises often reflect hepatic effects rather than muscle damage (which elevates creatine kinase instead).[2][4]
What Levels Require Monitoring or Action?
Guidelines recommend baseline liver tests before starting Lipitor, then rechecking at 12 weeks and as needed. Routine monitoring isn't required for all patients after that, per FDA updates. Discontinue if ALT/AST exceed 3x upper limit with symptoms (jaundice, fatigue) or 10x without.[1][5]
Does Lipitor Affect Other Liver Markers?
Lipitor rarely impacts alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), or bilirubin unless there's severe hepatotoxicity (under 0.5% cases). It's not linked to increases in these as primary effects.[2][3]
Risk Factors for Higher Elevations
Patients with obesity, diabetes, heavy alcohol use, or concurrent drugs (e.g., fibrates) face greater risk. Pre-existing liver disease contraindicates Lipitor use.[1][4]
Sources:
[1] Lipitor Prescribing Information (FDA)
[2] Drugs.com - Lipitor Side Effects
[3] StatPearls - Atorvastatin (NCBI)
[4] American Family Physician - Statin Hepatotoxicity
[5] FDA Drug Safety Communication on Statins